bluebird bio, Inc. (BLUE) Shares Sold by TD Asset Management Inc.
TD Asset Management Inc. cut its position in bluebird bio, Inc. (NASDAQ:BLUE) by 7.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,888 shares of the biotechnology company’s stock after selling 3,400 shares during the quarter. TD Asset Management Inc. owned approximately 0.09% of bluebird bio worth $5,753,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. FMR LLC boosted its position in shares of bluebird bio by 9.6% in the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after purchasing an additional 587,236 shares during the period. Capital Research Global Investors raised its stake in bluebird bio by 9.9% during the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after acquiring an additional 493,072 shares during the last quarter. Baillie Gifford & Co. raised its stake in bluebird bio by 3.8% during the 2nd quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after acquiring an additional 196,025 shares during the last quarter. Vanguard Group Inc. raised its stake in bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after acquiring an additional 343,856 shares during the last quarter. Finally, BlackRock Inc. raised its stake in bluebird bio by 4.3% during the 2nd quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after acquiring an additional 138,141 shares during the last quarter.
Several analysts have commented on BLUE shares. Goldman Sachs Group reaffirmed a “buy” rating and set a $186.00 price objective on shares of bluebird bio in a research note on Friday, October 6th. Jefferies Group reaffirmed a “buy” rating and set a $88.00 price objective on shares of bluebird bio in a research note on Friday, August 11th. Maxim Group reaffirmed a “buy” rating and set a $170.00 price objective (up from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. BMO Capital Markets upped their price objective on bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, BTIG Research raised bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price objective for the company in a research note on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $137.57.
bluebird bio, Inc. (BLUE) opened at $162.65 on Wednesday. bluebird bio, Inc. has a one year low of $60.95 and a one year high of $174.65.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The business had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business’s quarterly revenue was up 397.4% on a year-over-year basis. During the same period last year, the company posted ($2.07) earnings per share. equities analysts predict that bluebird bio, Inc. will post -6.68 EPS for the current year.
In related news, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.15, for a total value of $220,696.30. Following the sale, the chief operating officer now owns 13,718 shares in the company, valued at approximately $2,361,553.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey T. Walsh sold 4,900 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $125.73, for a total value of $616,077.00. Following the completion of the sale, the insider now owns 32,205 shares in the company, valued at approximately $4,049,134.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,450 shares of company stock valued at $15,790,373. Company insiders own 3.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Shares Sold by TD Asset Management Inc.” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/12/06/bluebird-bio-inc-blue-shares-sold-by-td-asset-management-inc.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.